retatrutide glp-1 gip glucagon triple agonist Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide to Weight Loss, Appetite Control & Metabolic Reset Retatrutide Research: Triple Agonist Mechanism
Description
Endocr Res 47(1):1825
DISCLOSURES: All authors have served as consultants for Galderma
Recovery capacity is the missing variable most people ignore
doi: 10.1016/j.biopha.2023.115567 191 KojimaYTanakaMSasakiMOzekiKShimuraTKubotaEet al
Within 10 years of T2DM diagnosis, 24.9% of people develop microalbuminuria, 5.3% develop macroalbuminuria, and 0.8% develop advanced CKD that includes persistently elevated plasma creatinine or the need for renal replacement therapy [4]
